Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
196.5 USD | -2.76% | -4.49% | -21.89% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 58% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 73.22 and 51.81 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.89% | 7.83B | C+ | ||
+73.27% | 12.36B | B- | ||
+14.67% | 7.21B | C- | ||
+4.77% | 5.97B | B | ||
+11.77% | 5.14B | D+ | ||
+29.65% | 4.43B | - | ||
-18.81% | 3.9B | B- | ||
-42.48% | 2.2B | C | ||
+1.24% | 2.02B | - | ||
+4.85% | 1.88B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PEN Stock
- Ratings Penumbra, Inc.